Table of Contents Table of Contents
Previous Page  171 / 258 Next Page
Information
Show Menu
Previous Page 171 / 258 Next Page
Page Background

976 

Gill & Indyk

: J

ournal of

AOAC I

nternational

Vol. 98, No. 4, 2015

Table 2. Collaborative study data for CMP in infant formulas

a

Lab No.

NIST 1849a

Lactose-free

Starch-based Hydrolysate-based Soy-based

b

Whey-based

Whey-based

1

27.88 27.97 11.09 11.12 10.75 10.73 9.61 9.63 0.49 0.47 5.20 5.25 5.17 5.21

2

29.60 29.10 9.52 9.48 10.49 9.43 10.3 10.10 0.00 0.00 4.55 4.40 3.94

c

3.56

c

3

27.46 26.90 10.71 10.50 9.90 9.98 9.60 9.53 0.00 0.00 6.23 5.98 5.05 4.81

4

29.66 30.45 12.40 12.40 11.90 12.30 10.70 10.90 1

.00 1.10 6.00 6.10 6.20 6.

00

5

28.77 28.65 12.84 13.12 11.92 11.92 10.91 10.20 0.58 0.78 5.86

d

6.41

d

6.24 6.14

6

27.80 28

.00 11.68 11.76 11.27

11.20 10.23 10.21 0.88 0.89 5.48 5.43 5.47 5.41

7

27.55 29.25 11.28 11

.00 11.28 11.22 9.49 8.

56 0.56 0.46 5.30 5.26 5.27 5.15

8

27.65 27.88 11.65 11.52 11.10 10.93 8.93 9.19 0.44 0.48 5.41 5.39 5.36 5.41

9

28.21 28.17 11.53 11.56 2.77

e

3.08

e

9.96 9.96 0.59 0.47 5.44 5.47 5.44 5.46

10

29.50 29.60 11.86 11.95 11.44 11.44 9.83 9.98 0.66 0.62 5.58 5.59 5.63 5.60

11

24.54 25.27 11.60 11.90 11.03 11.84 10.30 10.10 0.90 0.00 5.50 5.20 5.30 5.50

12

28.08 27.53 10.78 10.94 9.91 9.79 9.03 9.09 0.30 0.35 5.13 5.23 4.80 4.83

a

Concentration in mg/hg.

b

Product not fortified with CMP.

c

Identified as Grubbs outlier; results removed from data set for statistical analysis.

d

Identified as Cochran outlier; results kept in data set for statistical analysis.

e

Problems were identified by participants; identified as Grubbs outlier; results excluded from data set for statistical analysis.

Table 3. Collaborative study data for UMP in infant formulas

a

Lab. No.

NIST 1849a

Lactose-free

Starch-based Hydrolysate-based Soy-based

b

Whey-based

Whey-based

1

11.75 11.58 3.94 3.95 4.03 4.14 4.30 4.22 0.29 0.32 3.47 3.51 3.60 3.60

2

11.30 11.10 3.75 3.83 3.91 3.78 4.00 3.70 0.00 0.00 3.25 3.26 3.26

3.11

3

10.59 10.51 3.27 3.26 3.14

c

3.11

c

3.59 3.38 0.00 0.00 2.97 2.90 2.70

3.11

4

12.14 12.00 4.00 4.00 3.90 3.90 4.40 4.40 0.20 0.20 3.60 3.60 3.60 3.80

5

10.91 11.29 3.51 3.34 3.44

d

4.29

d

4.11

4.31 0.19 0.00 3.78 3.93 3.85 3.78

6

11.60 11.80 4.32 4.30 4.23 4.24 4.56 4.51 0.28 0.25 3.87 3.84 3.83 3.87

7

12.26 12.36 3.93 4.00 4.02 3.89 4.25 4.47 0.32 0.28 3.70 3.56 3.49 3.73

8

12.04 12.57 3.66 3.80 4.04 3.77 3.63 3.58 0.38 0.38 3.64 3.66 3.69 3.60

9

12.25 11.79 3.97 4.03 1.19

e

0.00

e

4.33 4.28 0.35 0.22 3.58 3.55 3.67 3.64

10

11.80 11.90 3.84 3.88 3.91 3.93 4.51

4.11

0.22 0.23 3.53 3.59 3.60 3.61

11

12.05 12.45 3.50 3.80 3.73 3.91 4.00 3.70 0.00 0.00 3.00 3.00 3.10 3.10

12

11.50 12.59 4.28 4.05 3.93 4.17 4.53 4.60 0.27 0.29 3.75 3.87 3.78 3.89

a

Concentration in mg/hg.

b

Product not fortified with UMP.

c

Identified as Cochran outlier; results kept in data set for statistical analysis.

d

Identified as Grubbs outlier; results removed from data set for statistical analysis.

e

Problems were identified by participants; identified as Grubbs outlier; results excluded from data set for statistical analysis.

Table 4. Collaborative study data for GMP in infant formulas

a

Lab No.

NIST 1849a

Lactose-free

Starch-based Hydrolysate-based Soy-based

b

Whey-based

Whey-based

1

14.31 14.40 1.39 1.39 1.59 1.60 1.33 1.35 0.26 0.32 1.01 1.01 0.99 1.02

2

15.80 15.50 1.50

c

1.40

c

1.78 1.78 1.40 1.40 0.00 0

.00 1.06 1.05 0.70 d

1.02

d

3

15.15 14.86 1.44 1.40 1.63 1.63 1.60 1.58 0.00 0

.00 1.13 1.13 1.12 1.17

4

14.77 15.36 1.50 1.50 1.70 1.70 1.40 1.40 0.00 0

.00 1.10 1.10 1.10 1.10

5

14.92 14.93 1.45 1.45 1.67 1.69 1.44 1.33 0.25 0.41 1.07 1.09 1.08 1.02

6

14.60 14.70 1.40 1.45 1.63 1.60 1.48 1.39 0.23 0.25 1.06 1.03 1.05 1.05

7

13.97 15.63 1.43 1.40 1.65 1.60 1.25

c

1.04

c

0.23 0.20 0.98 0.98 0.91 1.01

8

14.68 14.84 1.45 1.46 1.67 1.62 1.33 1.34 0.37 0.54 1.06 1.05 1.05 1.06

9

15.12 15.08 1.47 1.45 0.00

e

0.00

e

1.41 1.40 0.29

0.3

1.05 1.08 1.08 1.09

10

15.30 15.30 1.48 1.50 1.72 1.79 1.36 1.41 0.36 0.35 1.07 1.06 1.08 1.06

11

16.73 16.69 1.50 1.50 1.78 1.75 1.40 1.40 0.00 0.00 1.10

c

1.00

c

1.00 1.10

12

14.60 14.41 1.42 1.40 1.64 1.58 1.39 1.38 0.49 0.45 1.03 1.00 1.02 1.04

a

Concentration in mg/hg.

b

Product not fortified with GMP.

c

Identified as Cochran outlier; results kept in data set for statistical analysis.

d

Identified as Grubbs outlier; results removed from data set for statistical analysis.

e

Problems were identified by participants; identified as Grubbs outlier; results excluded from data set for statistical analysis.

171